The present invention relates to a process of synthesis of certain ionic liquids di-polymerized based Radziszewsky type reaction, whereby primary amines containing at least one terminal functional group, for example OH, aldehydes and a mineral or organic acid, react exothermically in a single step, thus resulting in an ionic liquid by condensation, then oxirane derivative molar quantities are added, by controlling the temperature and pressure a di-polymerized ionic liquid is obtained. The process of the present invention is advantageous because it provides a synthesis scheme for di-polymerized ionic liquids, primarily using short reaction times and high performance; this process can be further scaled for industrial production and it can accept alternative chemical precursors of lower cost.

An example of the general synthesis scheme of ionic liquids-propoxylated di (LI's) imidazolium follows:

##STR00001##

Whereby an efficiency greater than 96% of propoxylated ionic liquid is obtained, the product characterized by spectroscopic data.

The present invention relates to a process of synthesis of certain ionic liquids di-polymerized based Radziszewsky type reaction, whereby primary amines containing at least one terminal functional group, for example OH, aldehydes and a mineral or organic acid, react exothermically in a single step, thus resulting in an ionic liquid by condensation, then oxirane derivative molar quantities are added, by controlling the temperature and pressure a di-polymerized ionic liquid is obtained. The process of the present invention is advantageous because it provides a synthesis scheme for di-polymerized ionic liquids, primarily using short reaction times and high performance; this process can be further scaled for industrial production and it can accept alternative chemical precursors of lower cost.

An example of the general synthesis scheme of ionic liquids-propoxylated di (LI's) imidazolium follows:

##STR00001##

Whereby an efficiency greater than 96% of propoxylated ionic liquid is obtained, the product characterized by spectroscopic data.

Stable crystalline forms of a compound represented by the formula (IA):

##STR00001##

an acid addition salt, and/or a solvate thereof are provided by the present invention. Said crystalline forms are extremely useful as materials for preparing medicines. Novel processes for preparing 6,7-unsaturated-7-carbamoyl morphinan derivatives are also provided by the present invention.

Stable crystalline forms of a compound represented by the formula (IA):

##STR00001##

an acid addition salt, and/or a solvate thereof are provided by the present invention. Said crystalline forms are extremely useful as materials for preparing medicines. Novel processes for preparing 6,7-unsaturated-7-carbamoyl morphinan derivatives are also provided by the present invention.

Stable crystalline forms of a compound represented by the formula (IA):

##STR00001##

an acid addition salt, and/or a solvate thereof are provided by the present invention. Said crystalline forms are extremely useful as materials for preparing medicines. Novel processes for preparing 6,7-unsaturated-7-carbamoyl morphinan derivatives are also provided by the present invention.

Disclosed herein are salt and solid forms of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine. The solid form may be a salt and/or a crystalline form of V-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine, such as a polymorph of N-eth-yl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine or a salt thereof. Also disclosed are methods for making the salts and solid forms and methods for administering the same. The solid forms of V-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine are useful for treating neurological disease and/or a psychiatric disorder in a subject.

Method for producing an iron carboxylate, whereby it becomes possible to prevent the generation of hydrogen during the production of the iron carboxylate by the reaction of a carboxylic acid with metal iron. An embodiment of the present invention is a method for producing an iron carboxylate by reacting metal iron with a carboxylic acid in a reaction solution, wherein the reaction solution contains a non-iron metal having a standard electrode potential of 2.5 to 0.1 inclusive or a metal compound containing the metal, or the reaction solution contains at least one metal selected from the group consisting of Ag, Bi and Pd or a metal compound containing the metal.

Method for producing an iron carboxylate, whereby it becomes possible to prevent the generation of hydrogen during the production of the iron carboxylate by the reaction of a carboxylic acid with metal iron. An embodiment of the present invention is a method for producing an iron carboxylate by reacting metal iron with a carboxylic acid in a reaction solution, wherein the reaction solution contains a non-iron metal having a standard electrode potential of 2.5 to 0.1 inclusive or a metal compound containing the metal, or the reaction solution contains at least one metal selected from the group consisting of Ag, Bi and Pd or a metal compound containing the metal.

The present invention generally relates to novel synthetic methods, systems, kits, salts, and precursors useful in medical imaging. In some embodiments, the present invention provides compositions comprising an imaging agent precursor, which may be formed using the synthetic methods described herein. An imaging agent may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in .sup.18F. In some cases, an imaging agent including salt forms (e.g., ascorbate salt) may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

The present invention generally relates to novel synthetic methods, systems, kits, salts, and precursors useful in medical imaging. In some embodiments, the present invention provides compositions comprising an imaging agent precursor, which may be formed using the synthetic methods described herein. An imaging agent may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in .sup.18F. In some cases, an imaging agent including salt forms (e.g., ascorbate salt) may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.